SCHEMBL4587382

SCHEMBL4587382

C[C@@H](O)[C@H](N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)[O-].C[C@@H](O)[C@H](N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)[O-].[Mn+2]

nearest known ligand 0.41

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC15A2 Q16348 1/20 0.41
GHSR Q92847 7/20 0.34
MMP1 P03956 1/20 0.34
OPRK1 P41145 4/20 0.33
OPRM1 P35372 2/20 0.33
ERAP2 Q6P179 1/20 0.33
ERAP1 Q9NZ08 1/20 0.33
LNPEP Q9UIQ6 1/20 0.33
PLG P00747 1/20 0.33
REN P00797 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5969804 0.98 SLC15A2 (0.41) SLC15A2GHSRMMP1OPRK1OPRM1
SCHEMBL4588264 0.94 SLC15A2 (0.41) SLC15A2GHSRMMP1OPRK1OPRM1
SCHEMBL2242457 0.92 SLC15A2 (0.41) SLC15A2GHSRMMP1OPRK1OPRM1
SCHEMBL4588260 0.92 SLC15A2 (0.42) SLC15A2GHSRMMP1ERAP2ERAP1
SCHEMBL4589867 0.92 PLG (0.40) SLC15A2GHSRMMP1OPRK1OPRM1
SCHEMBL2247601 0.90 SLC15A2 (0.42) SLC15A2GHSRMMP1ERAP2ERAP1
SCHEMBL5969687 0.90 PLG (0.40) SLC15A2GHSRMMP1OPRK1OPRM1
SCHEMBL4587314 0.89 SLC15A2 (0.39) SLC15A2GHSROPRK1ERAP2ERAP1
SCHEMBL4588807 0.87 SLC15A2 (0.41) SLC15A2GHSROPRK1
SCHEMBL4587124 0.87 SLC15A2 (0.54) SLC15A2GHSRMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2008-10-16 US disclosed
US-7384916-B2 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2008-06-10 US disclosed
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2006-11-02 US disclosed
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin PROCYTE CORPORATION (US) 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin RBP1, RBP4, SOD1 SLC15A2 2656/4885GHSR 1411/4885MMP1 625/4885
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin RBP1, RBP4, MC1R SLC15A2 1582/4885GHSR 748/4885MMP1 1224/4885
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN RBP1, RBP4, SOD1 SLC15A2 2656/4885GHSR 1411/4885MMP1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.